echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Gilead Trodelvy receives FDA approval to treat triple-negative breast cancer

    Gilead Trodelvy receives FDA approval to treat triple-negative breast cancer

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Gilead Sciences announced that the US FDA has fully approved the targeted anti-cancer drug Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).


    The approval of Trodelvy was supported by data from a global, open-label Phase III ASCENT trial.


    In terms of safety, in all ASCENT trial patients (n = 482), the trial results showed that the safety of Trodelvy was consistent with other indications approved by the FDA.


    Trodelvy is a new and pioneering antibody-conjugated drug (ADC) targeting Trop-2.


    In addition, Trodelvy’s application for a new indication is also under review by the US FDA for the treatment of neoadjuvant/adjuvant, metastatic diseases that have previously received platinum-containing chemotherapy and PD-1 inhibitors or PD-L1 inhibition.


    In addition to the good news in the US market, the drug is also expected to make progress in the European Union.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.